Q2 2025 Management View CEO Dig Howitt highlighted a 6% increase in net sales on a constant currency basis, driven by 13% growth in Cochlear implant revenue and 22% growth in Acoustics revenue.

Cochlear (ASX: COH) shares are trading at the lowest level since December 2023 after the company reported a ...

RBC Capital markets adjusted their stance on Cochlear Ltd. (COH:AU) (OTC: CHEOY), a $10.9 billion medical device company ...

Cochlear Limited (ASX: COH) has reported a 5 percent increase in revenue to $1,170 million for the first half of the 2025 ...

Shareholder distributions are appropriate. Capital intensity of the industry remains low and gross margins high. In addition, Cochlear enjoys high cash conversion, enabling it to typically pay out 70% ...

The Hong Kong Patent Office granted HK Patent No. HK40097814 to Envoy Medical Corporation on January 3, 2025. The title is Programming of Cochlear Implant Accessories. This patent relates to a system ...

The Cochlear Ltd (ASX: COH ... The introduction of the new off-the-ear Nucleus Kanso 3 Sound Processor from mid-2025 is expected to contribute to Services revenue from FY26.

The Director-General of the Dubai Health Authority, DHA, and Chairman of the Board, Humaid Al Qutami, today inaugurated the 1st International Arabic Cochlear Implant Conference, ACIC, in Dubai. The ...

An infant fitted with a cochlear implant. He would like to see an uncapped system, however has suggested that incrementally increasing the cap to $250m would be a good start. Mr Howitt said ...

The broker noted that the Cochlear implant unit growth was 6% year over year with stable pricing. The company continues to expect growth of around 10% for FY25, implying an uplift in the second half.